Pfizer is acquiring two Baxter vaccines
Pfizer is acquiring two Baxter vaccines. The deal worth $635 mln will transfer rights as well as part of the factory in Austria where the vaccines are made. NeisVac-C helps protect against meningitis caused by group C meningococci. FSME-IMMUN/TicoVac is used to prevent tick-borne encephalitis. 120 million doses of the vaccine were sold in 30 countries since 1976. Pfizer current vaccine portfolio includes Prevnar 13 for pneumococcal infection prophylaxis, HibTITER for protection against Haemophilus influenzae type b, DTPa Acel-Imune and others. The acquisition of complementary products will increase patient coverage with all company vaccines.
Sources: Remedium, EvaluatePharma®